Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ISA 2020 | AL amyloidosis: Hot topics from ISA 2020

Vaishali Sanchorawala • 15 Sep 2020
ISA 2020
Amyloidosis Rare Diseases

Big topics for discussion at this year’s ISA meeting include measurable residual disease (MRD) assessment and hematological response measurement in AL amyloidosis. Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses these hot topics from ISA 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Vaishali Sanchorawala

Updated results with the bispecific antibody etentamig in patients with R/R AL amyloidosis 2:17
Updated results with the bispecific antibody etentamig in patients with R/R AL amyloidosis
Vaishali Sanchorawala • 8 Dec 2025
Cardiac safety of two Dara-VCd dosing schedules in newly diagnosed AL amyloidosis: AQUARIUS trial 5:43
Cardiac safety of two Dara-VCd dosing schedules in newly diagnosed AL amyloidosis: AQUARIUS trial
Vaishali Sanchorawala • 8 Dec 2025
Key agents of interest in the AL amyloidosis space with trial updates presented at ASH 2025 1:03
Key agents of interest in the AL amyloidosis space with trial updates presented at ASH 2025
Vaishali Sanchorawala • 8 Dec 2025
Amyloidosis Sessions: Highlights from ASH 2024
Ashutosh Wechalekar et al. • 8 Dec 2024

Related Videos

Using artificial intelligence to accelerate patient eligibility screening in clinical trials 1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
Molecular classification of Waldenström’s macroglobulinemia: the identification of two subtypes 2:03
Molecular classification of Waldenström’s macroglobulinemia: the identification of two subtypes
Gareth Morgan • 7 Dec 2025
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals